Vertex Adds To Myotonic Dystrophy Effort With Entrada Collaboration
Executive Summary
Entrada gets $250m cash and equity up front under four-year deal, which extends its runway and will enable it to focus on Duchenne muscular dystrophy. Vertex further diversifies its pipeline with a novel drug class.